ANAPTYSBIO INC (ANAB)
US0327241065 - Common Stock
Overall ANAB gets a fundamental rating of 3 out of 10. We evaluated ANAB against 574 industry peers in the Biotechnology industry. While ANAB has a great health rating, there are worries on its profitability. While showing a medium growth rate, ANAB is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ANAB has reported negative net income.
ANAB had a negative operating cash flow in the past year.
In the past 5 years ANAB always reported negative net income.
ANAB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ANAB's Return On Assets of -39.80% is in line compared to the rest of the industry. ANAB outperforms 56.51% of its industry peers.
ANAB's Return On Equity of -1722.01% is on the low side compared to the rest of the industry. ANAB is outperformed by 83.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.8% | ||
| ROE | -1722.01% | ||
| ROIC | N/A |
ROA(3y)-22.08%
ROA(5y)-18.68%
ROE(3y)-83.68%
ROE(5y)-56.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ANAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ANAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANAB has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ANAB has been reduced compared to 5 years ago.
ANAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.07, we must say that ANAB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.07, ANAB perfoms like the industry average, outperforming 55.81% of the companies in the same industry.
There is no outstanding debt for ANAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.07 |
ROIC/WACCN/A
WACC10.31%
2.3 Liquidity
A Current Ratio of 9.09 indicates that ANAB has no problem at all paying its short term obligations.
With a decent Current ratio value of 9.09, ANAB is doing good in the industry, outperforming 77.11% of the companies in the same industry.
ANAB has a Quick Ratio of 9.09. This indicates that ANAB is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 9.09, ANAB is doing good in the industry, outperforming 77.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.09 | ||
| Quick Ratio | 9.09 |
3. Growth
3.1 Past
The earnings per share for ANAB have decreased strongly by -22.35% in the last year.
The Revenue has grown by 135.69% in the past year. This is a very strong growth!
The Revenue has been growing by 27.97% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-22.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14%
Revenue 1Y (TTM)135.69%
Revenue growth 3Y-38.84%
Revenue growth 5Y27.97%
Sales Q2Q%217.08%
3.2 Future
ANAB is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.59% yearly.
Based on estimates for the next years, ANAB will show a very strong growth in Revenue. The Revenue will grow by 54.24% on average per year.
EPS Next Y-12.47%
EPS Next 2Y-7.42%
EPS Next 3Y-5.16%
EPS Next 5Y-1.59%
Revenue Next Year214.03%
Revenue Next 2Y68.29%
Revenue Next 3Y51.86%
Revenue Next 5Y54.24%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ANAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANAB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ANAB's earnings are expected to decrease with -5.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.42%
EPS Next 3Y-5.16%
5. Dividend
5.1 Amount
No dividends for ANAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ANAPTYSBIO INC
NASDAQ:ANAB (9/6/2024, 5:03:52 PM)
After market: 35.9 0 (0%)35.9
-0.89 (-2.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap980.79M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.8% | ||
| ROE | -1722.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.09 | ||
| Quick Ratio | 9.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-22.35%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-12.47%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)135.69%
Revenue growth 3Y-38.84%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y